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Abstract
Aim: To compare the efficacy and safety of two misopros-
tol dosing regimens for induction of labour in primiparous 
(1P) and multiparous ( > 1P) women.
Methods: Retrospective study of induction of labour 
using vaginal misoprostol 25 μg vs. 50 μg every 6 h in 942 
women at a tertiary centre. The main outcome variables 
are induction-to-delivery interval, latency period dura-
tion, vaginal delivery within 24 h, and maternal and foetal 
safety outcome.
Results: With the 50 μg regimen, induction-to-delivery 
intervals were significantly shorter: 18.4 h vs. 24.6 h (1P) 
and 14 h vs. 17.9 h ( > 1P), as was latency period duration (by 
5.4 and 4 h, respectively). Vaginal delivery within 24 h was 
significantly more frequent, as were non-reassuring foetal 
heart rate (1P: 20% vs. 14%) and tachysystole (1P: 31% vs. 
11%;  > 1P: 21% vs. 7%). No uterine rupture was reported. 
Neonatal outcomes were similar except for significantly 
more frequent infant referral to neonatal intensive care in 
the  > 1P group receiving the 50 μg regimen (11% vs. 4%).
Conclusion: Vaginal misoprostol 25 μg seems to main-
tain efficacy with more acceptable maternal and neona-
tal safety. As induction of labour is an off-label use for 
misoprostol, safety should be prioritised with the lower 
dosage regimen despite the longer induction-to-delivery 
interval.
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Introduction
Labour is often induced in order to reduce the risk of 
maternal or neonatal morbidity and mortality. One of 
the most commonly used agents is misoprostol [11], a 
 synthetic prostaglandin structurally related to prosta-
glandin E1. Originally licensed as an oral treatment for 
gastric ulcers [27], it is used off-label worldwide in obstet-
rics [28]. Misoprostol binds selectively to prostanoid 
receptors, increases intracellular calcium and contracts 
myometrium [5, 22], while also softening the cervix by 
collagen disintegration and dissolution [7]. As a result, 
it shortens the induction-to-delivery interval compared 
to placebo, oxytocin or other induction agents in women 
with an unfavourable cervix [14]. Misoprostol can be 
applied by various routes and at various doses [6, 12, 24]. 
Because of its efficacy, cost-effectiveness, easy storage at 
room temperature and easy administration, misoprostol 
is listed as an essential medication by the World Health 
Organization [25, 29, 30].
However, complications when using misoprostol for 
induction of labour have aroused frequent debates result-
ing from its off-label use [28]. They include uterine tachy-
systole or hyperstimulation syndrome, uterine rupture, 
need for instrumental vaginal delivery or caesarean 
section and low Apgar scores or umbilical artery (UA) pH 
with referral to a neonatal intensive care unit. The risk of 
adverse effects seems to be dose-related and increases 
with repeated doses of 50 μg or above [14]. Furthermore, 
parity appears a major outcome determinant, with not 
only induction intervals, including latent and active 
phases, being significantly longer in primiparous (1P) 
women, but also labour itself usually being longer [12], 
with higher rates of instrumental vaginal delivery and 
caesarean section than in multiparous ( > 1P) women [15].
We performed this study to compare the efficacy and 
safety of a 25 μg vs. 50 μg regimen of intravaginal miso-
prostol for induction of labour at term and to evaluate the 
clinical outcome in 1P and  > 1P women.
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Materials and methods
We based this retrospective study on a review of the medical records 
of all women with induced labour at a Swiss tertiary hospital 
between January 2007 and December 2011, identified using PERI-
NAT, an in-hospital patient record system, version 5.0 (University 
Hospital Zurich, Switzerland) [32]. Demographic and obstetric data 
of all women induced with misoprostol were collected [maternal 
age, body mass index, parity, gestational age (GA) at delivery, birth 
weight, and reasons for induction]. Inclusion criteria were term 
gestation ( ≥  37 weeks), singleton foetus in vertex presentation, and 
absence of active labour. Exclusion criteria were multiple pregnancy, 
previous uterine surgery (e.g., caesarean section and myomectomy), 
changes in regimen for induction of labour or incomplete data. 
Patients were informed about the induction procedure including the 
off-label use of misoprostol and its potential risks (hyperstimulation 
syndrome, uterine rupture and caesarean section).
Until mid-2010 our hospital administered misoprostol 50 μg 
vaginally every 6 h until labour onset in women with an unfavourable 
cervix (Bishop score  ≤  7). Cardiotocography was performed 30  min 
before and 60 min after each dose. The procedure was repeated after 
6 h in the absence of contractions and if the Bishop score was  ≤  7. 
No further dose was given if contractions exceeded 2 per 10 min or 
if there were foetal heart rate abnormalities. In the presence of  > 2 
contractions per 10 min, failure of cervical dilatation ( < 1 cm/h) or 
failure to progress during the active first and second stage of labour, 
management required initiation of intravenous oxytocin by infusion 
pump at increasing doses from 0.002 international units per minute 
(IU/min) to a maximum of 0.018 IU/min beginning  > 6 h after the last 
dose of misoprostol. Cardiotocography was continuous in the active 
phase of labour (cervical dilatation  > 3 cm with regular uterine con-
tractions) and after initiation of the oxytocin infusion.
Since mid-2010 there is a population bias as we have followed a 
procedure that was identical in every respect except in giving 25 μg 
misoprostol instead of 50 μg doses. But this change allowed us to 
compare the efficacy and safety between the two regimens.
Outcome parameters were the induction-to-delivery interval 
(from insertion of first misoprostol tablet to delivery), latency period 
duration (from insertion of first misoprostol tablet to onset of the 
active phase of labour), duration of labour, vaginal delivery within 
24 h, mode of delivery, uterine tachysystole ( > 5 contractions per 10 
min), hyperstimulation syndrome (uterine tachysystole with non-
reassuring foetal heart rate), uterine rupture, 5-min Apgar score  < 7, 
UA pH  < 7.15 and neonatal intensive care referral rate.
Patients exhibiting tachysystole were monitored closely. 
Tachysystole  > 20  min was treated by reducing the oxytocin infu-
sion. Hyperstimulation syndrome was managed by terminating the 
oxytocin infusion, changing maternal position, giving oxygen by 
face mask and/or administering hexoprenaline in 5–10 μg doses 
 intravenously.
Further outcomes were the total dose of misoprostol required, 
the requirement for oxytocin and epidural anaesthesia (EDA), and 
the presence of meconium-stained amniotic fluid. Complications 
such as shoulder dystocia, retained products of conception, postpar-
tum bleeding (difference between pre- and postpartum haemoglobin, 
Hb) and third or fourth degree perineal tears were also recorded.
The data analysis used SPSS (version 20, SPSS, Zurich, Switzer-
land). Results were reported as means ± standard deviation, median, 
interquartile range and percentage. The groups were compared 
using contingency table and chi-squared (Fisher’s exact test) analy-
sis for categorical and binary values. Quantitative variables were 
tested for normality by Kolmogorov-Smirnov and Shapiro-Wilk tests. 
Differences in medians of quantitative variables between groups 
were tested by a nonparametric Mann-Whitney test. Two-sided 
P-values were reported for all tests. Values  ≤  0.05 were regarded as 
significant.
Ethical approval was given for the retrospective study using 
anonymised data.
Results
Between January 2007 and December 2011, 1435 women 
were induced at term with vaginal misoprostol at the Uni-
versity Hospital Zurich. The exclusion criteria reduced the 
final sample size to 942 (Figure 1) – 437 of whom received 
25 μg doses and 505 received 50 μg doses.
Baseline demographics and indications for induction 
were similar in both groups (Table 1).
Outcome parameters (Table 2) showed that regardless 
of the mode of delivery, 73% of all women (1P: 66.7%;  > 1P: 
84.1%) had an induction-to-delivery interval  < 24 h, and 
95% and 99.1%, respectively, had an interval  < 48 h.
The latency period and the induction-to-delivery 
interval were both significantly shorter in both parity 
groups receiving 50 μg vs. 25 μg. For the latency period: 
11.2 ± 7.2 vs. 16.6 ± 14.3, P < 0.001 (1P) and 9.7 ± 6.8 vs. 13.6 ± 15.6 
P < 0.01 ( > 1P). For the induction-to-delivery interval, 18.4 h 
vs. 24.6 h, P < 0.001 (1P) and 14 h vs. 17.9 h, P < 0.01 ( > 1P). 
Significantly more women given 50 μg delivered within 
24 h: 77.6% vs. 54.7%, P < 0.001 (1P) and 89.9% vs. 76.7%, 
P < 0.01 ( > 1P). Rates of vaginal delivery within 24 h were 
significantly higher with 50 μg: P < 0.001 and P < 0.01, 
respectively. The 25 μg and 50 μg groups did not differ in 
the mode of delivery.
In the 50 μg group, non-reassuring foetal heart rates 
were significantly more frequent in 1P women (19.6% vs. 
13.6%, P = 0.05) as was uterine tachysystole in both 1P 
and  > 1P women (30.9% vs. 10.8%; 20.8% vs. 7.3%, both 
P = 0.001). There were no cases of uterine rupture in any 
group.
There were no significant intergroup differences in 
5-min Apgar score  < 7 or UA pH  < 7.15. In  > 1P women sig-
nificantly more infants were referred to the neonatal 
intensive care unit in those given 50 μg (11.2% vs. 4.2%, 
P < 0.05).
Total dosage requirements (Figure 2) showed that with 
the 50 μg regimen 83% and 87% of 1P and  > 1P women 
delivered after a single dose; with the 25 μg regimen 81% 
and 88%, respectively, required  ≤  50 μg of misoprostol.
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Figure 1 Breakdown of all women being induced with misoprostol between 2007 and 2011 at term.
In 1P women, the requirement for additional oxytocin 
(84.2% vs. 73.5%, P = 0.001) and EDA (61.4% vs. 51.1%, 
P < 0.01) were significantly greater with the 25 μg regimen.
Rates of other clinical outcomes, such as meconium-
stained amniotic fluid, shoulder dystocia, retained prod-
ucts of conception or third or fourth degree perineal tears, 
were similar in both groups, except for greater postpartum 
haemorrhage in 1P women given 25 μg vs. 50 μg (Hb differ-
ence 1.9 ± 1.6 g/dL vs. 1.4 ± 1.4 g/dL, P < 0.001).
Discussion
Our results show that a 25 μg regimen of vaginal misopros-
tol is safe for induction of labour. In 1P women, it reduced 
the side effects of tachysystole by two-thirds and hyper-
stimulation syndrome by one-third compared to a 50 μg 
dose regimen. However, it significantly lengthened the 
latency period (by about 6 and 4 h in 1P and  > 1P women) 
and, therefore, lengthened the induction-to-delivery 
interval (by 6 and 4 h, respectively).
These results support the 75% decrease in tachy-
systole (12% vs. 3%) reported in 147 women given 25 μg 
instead of 50 μg misoprostol vaginally every 4 h, together 
with a similar prolongation of the induction-to-deliv-
ery interval (+4 h) [8]. A 2002 meta-analysis of 5 ran-
domised clinical trials also reported an almost 5 h shorter 
induction-to-delivery interval in women receiving 50 μg 
misoprostol instead of 25 μg [21]. Rates of abnormal con-
tractility pattern, tachysystole (21% vs. 9%) and uterine 
hyperstimulation syndrome (9% vs. 4%) were higher with 
the 50 μg regimen. One study in the meta-analysis showed 
a 50% reduction in tachysystole in the 25 μg group (32.8% 
vs. 15.6%; P < 0.001) but no reduction in hyperstimulation 
syndrome [9]. Unfortunately, the study did not test for 
the effect of parity, in which case it may have concluded 
differently, bearing in mind the one-third reduction in 
hyperstimulation syndrome that we found exclusively in 
1P women (19.6% vs. 13.6%, P = 0.05).
Meydanli et  al. found no significant increase 
(P = 0.09) in induction-to-delivery interval with the 4-h 
25 μg regimen in a population of 120 1P and  > 1P women 
[18]. Rates of tachysystole, hyperstimulation syndrome 
and oxytocin requirement were also similar with both the 
regimens. However, the exclusion criteria were excessive, 
EDA was not performed and only women with GA  > 41 
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Table 1 Baseline characteristics of the study population.
Characteristics  
 
IP  
 
 > IP
25 μg (n = 287)   50 μg (n = 317) 25 μg (n = 150)   50 μg (n = 188)
Age (years)        
 (mean ± SD)   30.1 ± 5.9   29.6 ± 5.6   31.7 ± 5.4   32.5 ± 5.0
 (median, IQR)   30.0, 10.0   30.0, 8.0   32.0, 8.0   33.0, 7.0
BMI (kg/m2)        
 (mean ± SD)   22.8 ± 4.4   23.3 ± 4.4   24.5 ± 4.5   24.4 ± 4.3
 (median, IQR)   21.8, 3.9   22.3, 5.0   23.8, 6.1   23.4, 5.5
Gestation (weeks)        
 (mean ± SD)   40.4 ± 1.3   40.2 ± 1.4   39.9 ± 1.4   39.8 ± 1.5
 (median, IQR)   40.6, 1.9   40.6, 2.4   40.1, 2.7   39.9, 2.8
Birth weight (kg)        
 (mean ± SD)   3.4 ± 0.5   3.4 ± 0.5   3.5 ± 0.5   3.5 ± 0.5
 (median, IQR)   3.4, 0.7   3.4, 0.7   3.5, 0.8   3.5, 0.7
Bishop Score        
 (mean ± SD)   2.4 ± 1.5   1.9 ± 1.3   2.5 ± 1.5   2.2 ± 1.4
 (median, IQR)   2.0, 2.0   2.0, 2.0   2.0, 2.0   2.0, 2.0
Indication for induction of labour, n(%)
 Rupture of membranes   75 (26.1%)   71 (22.4%)   26 (17.3%)   25 (13.3%)
 Post date   102 (35.5%)   111 (35.0%)   42 (28.0%)   51 (27.1%)
 Foetal malformations   12 (4.2%)   15 (4.7%)   5 (3.3%)   15 (8.0%)
 Oligohydramnion   29 (10.1%)   34 (10.7%)   14 (9.3%)   14 (7.5%)
 Preeclampsia   10 (3.5%)   16 (5.1%)   6 (4.0%)   7 (3.7%)
 On request   16 (5.6%)   14 (4.4%)   21 (14.0%)   26 (13.8%)
 Gestational diabetes   8 (2.8%)   18 (5.7%)   10 (6.7%)   16 (8.5%)
 Diabetes mellitus   3 (1.1%)   9 (2.8%)   5 (3.3%)   5 (2.7%)
 IUGR   7 (2.4%)   5 (1.6%)   3 (2.0%)   4 (2.1%)
 Cholestasis of pregnancy   9 (3.1%)   6 (1.9%)   4 (2.7%)   3 (1.6%)
 Othersa   16 (5.6%)   18 (5.7%)   14 (9.4%)   22 (11.7%)
  (P = 0.41)   (P = 0.76)
aExamples: infection, suspect foetal heart rate pattern, macrosomia, vaginal bleeding, blood group incompatibility, maternal  indication 
(each below 2%). BMI = body mass index (kg/m2), IQR = interquartile range, IUGR = intrauterine growth restriction, IP = primiparous 
women,  > IP = multiparous women, SD = standard deviation.
weeks were included, which may have compromised the 
data.
Loto et al. [16] reported also a significantly shorter 
induction-to-delivery interval with the 50 μg regimen than 
with 25 μg (8.2 ± 1.5 h vs. 9.09 ± 2.7 h). In that study, however, 
the induction of labour was conducted in patients with a 
favorable cervix (Bishop Score  > 7), which could explain 
the shorter interval compared to our results [16].
Uterine hyperstimulation has been accused of 
increasing the caesarean section or other operative 
delivery rates [10]. At least one study has shown a 
decrease in section rates with the 25 μg regimen [23]. We 
could confirm neither a decrease in section rates nor an 
increase in vaginal operative delivery rates, in line with 
other studies showing that high- and low-dose regimens 
were equally effective in inducing labour [18, 21]. We 
even found that about 15% more women delivered vagi-
nally within 24  h of induction with the 50 μg regimen. 
The 50 μg dose is considered more effective in its direct 
effect on the cervix [18] and it is presumably quicker to 
reach the threshold plasma misoprostol acid concentra-
tion. However, plasma misoprostol concentrations have 
been reported to decline to a mean 61% of peak levels 4 h 
after vaginal administration [18, 31]; so repeated 25 μg 
doses may initiate contractions by reaching the thresh-
old level at a later stage. Thus it is not surprising to 
observe more women with the 50 μg regimen delivering 
vaginally after a single dose of misoprostol and within 
24 h of induction. The significantly higher number of 1P 
women requiring oxytocin with the 25 μg regimen also 
points to the stronger uterine stimulation achieved by 
higher misoprostol doses.
A serious complication of abnormal uterine contractility 
due to labour induced with misoprostol is uterine rupture, 
especially after previous caesarean section ( ≤  5.6%) [19, 20]. 
It can also occur in an unscarred uterus after a single dose of 
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Table 2 Outcome after induction of labour with either 25 or 50 μg of misoprostol for primi- (1P) and multiparous ( > 1P) women.
IP  > IP
25 μg   50 μg   P-value 25 μg   50 μg   P-value
Latency period (h)          
 (mean ± SD) 16.6 ± 14.3   11.2 ± 7.2    < 0.001   13.6 ± 15.6   9.7 ± 6.8    < 0.01
 (median, IQR) 12.6 ± 12.1   9.9, 8.4     10.5, 10.0   7.9, 6.1  
Induction-to-delivery interval (h)          
 (mean ± SD) 24.6 ± 15.2   18.4 ± 8.9    < 0.001   17.9 ± 16.1   14.0 ± 8.9    < 0.01
 (median, IQR) 20.8, 14.8   6.6, 10.9     14.3, 12.1   12.0, 8.7  
Length of labour (h)          
 (mean ± SD) 7.7 ± 4.8   6.8 ± 4.1   0.16   4.3 ± 4.3   4.4 ± 4.4   0.89
 (median, IQR) 7.4, 6.1   6.0, 5.5     2.8, 4.6   3.0, 3.9  
Delivery  < 24 h (%) 54.7   77.6    < 0.001   76.7   89.9    < 0.01
Vaginal delivery  < 24 h (%) 43.6   58.1    < 0.001   72.0   85.6    < 0.01
Vaginal delivery (%) 42.5   50.8     86.7   88.9  
Vaginal operative delivery (%) 28.6   21.8     6.0   6.9  
Caesarean delivery (%) 28.9   27.4   0.08   7.3   4.3   0.46
Uterine tachysystole (%) 10.8   30.9    < 0.001   7.3   20.7   0.001
Uterine hyperstimulation (%) 13.6   19.6   0.05   8.7   9.6   0.85
5-min Apgar score  < 7 (%) 1.0   1.9   0.51   1.4   1.2   1.00
Umbilical artery pH  < 7.15 (%) 7.1   9.4   0.36   5.5   6.7   0.82
Admission into neonatal unit (%) 5.9   6.3   0.87   4.2   11.2    < 0.05
Oxytocin augmentation (%) 84.2   73.5   0.001   56.7   52.7   0.51
EDA (%) 61.4   51.1    < 0.05   30.2   35.1   0.39
Meconium-stained liquor (%) 24.5   18.4   0.19   16.2   13.5   0.78
Shoulder dystocia (%) 0.3   0.9   0.63   2.7   0.5   0.18
Retained placenta (%) 3.8   3.8   1.00   5.3   4.3   0.80
Third or fourth degree perineal tears (%) 1.0   0.9   1.00   0.7   0.5   1.00
Postpartum haemorrhage (Hb difference)          
 (mean ± SD) 1.9 ± 1.6   1.4 ± 1.4    < 0.001   1.2 ± 1.3   1.2 ± 1.2   0.42
 (median, IQR) 1.6, 1.8   1.2, 1.7     1.0, 1.7   1.0, 1.6  
EDA = epidural anaesthesia, Hb = haemoglobin.
either 50 μg or even 25 μg, but few cases have been reported 
[4, 17, 26]. None occurred in our study.
Despite the increased rate of uterine contractile 
abnormalities associated with the 50 μg regimen in our 
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Figure 2 Dosage requirements within the two different protocols 
(25 vs. 50 μg misoprostol) for primi- and multiparous women.
study, overall neonatal outcomes were similar, with com-
parable Apgar scores and UA pH, as in other studies [16, 
18, 21]. However, in the  > 1P group referral rates to neona-
tal intensive care were significantly higher with the 50 μg 
regimen (11.2% vs. 4.2%). One explanation could be that 
more women in the 50 μg group (n = 15, 8% vs. n = 5, 3.3%) 
were induced for foetal malformation. These infants were 
automatically referred to neonatal intensive care for safety 
reasons or for further treatment caused by their known 
malformations.
Our results concur with the 2010 Cochrane review of 
seven studies comparing vaginal misoprostol 25 μg vs. 
50 μg 3–6  h [11] which showed less tachysystole and 
hyperstimulation syndrome, more failure to achieve deli-
very within 24  h and significantly more use of oxytocin 
with the lower-dose regimen. It also found no differences 
in mode of delivery, meconium-stained liquor or maternal 
side-effects.
The 25 μg regimen extends the induction-to-delivery 
interval, which can be exhausting for the women. It is 
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recommended for reducing side effects such as tachysys-
tole and hyperstimulation syndrome [2, 30], although an 
optimal dosage regimen has not been firmly established. 
An alternative could be to combine pharmacological and 
mechanical techniques such as an intracervical Foley 
catheter or double-balloon catheter to shorten the latency 
period while avoiding tachysystole or hyperstimulation 
syndrome. Hence, there are recent studies evaluating the 
role of adjuvant interventions to shorten the overall dura-
tion of induced labour and also to improve the outcome by 
using lower dosages of misoprostol [1, 3, 13].
Our study is one of the largest to compare the effi-
cacy and safety of inducing labour with a 25 μg vs. 50 μg 
regimen of vaginal misoprostol in the two parity groups. 
But it also has its limitations: it is a retrospective non-
randomised study subject to confounding bias. We plan a 
randomised controlled study using combinations of tech-
niques for induction of labour.
Conclusion
The 25 μg regimen of vaginal misoprostol appears to 
maintain efficacy with more acceptable maternal and 
neonatal safety. Given that induction of labour is an off-
label use, safety should be prioritised despite the longer 
induction-to-delivery interval. More research is required 
to optimise misoprostol management, potentially with 
adjuvant interventions that shorten the induction-to-
delivery interval while securing safe maternal and foetal 
outcomes.
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